Screener
Veracyte VCYT Business Segments — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Testing revenue | $135,091 | $107,309 |
| Product revenue | 3,679 | 3,580 |
| Biopharmaceutical and other revenue | 301 | 3,584 |
| Total revenue | 139,071 | 114,473 |
| Cost of revenue: | ||
| Cost of testing revenue: | ||
| Laboratory supplies and reagents expense | 12,314 | 13,067 |
| Sample collection expense | 3,288 | 2,825 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's business segments — total revenue?
- Veracyte (VCYT) reported business segments — total revenue of $139.07M in Q1 2026.
- How has Veracyte's business segments — total revenue changed year-over-year?
- Veracyte's business segments — total revenue increased by 21.5% year-over-year, from $114.47M to $139.07M.
- What is the long-term trend for Veracyte's business segments — total revenue?
- Over 3 years (2022 to 2025), Veracyte's business segments — total revenue has grown at a 20.4% compound annual growth rate (CAGR), from $296.54M to $517.15M.
- What does business segments — total revenue mean?
- Represents the total gross income generated by the reportable business segment from its primary operations. This figure reflects the segment's market demand and ability to monetize its products or services before accounting for any operating expenses.
Ask your AI about Veracyte's business segments — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude